Compare Incyte Corporation (INCY) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Palantir Technologies Inc — how do they compare? Incyte Corporation trades at $121.12 (market cap $24.54B), while Palantir Technologies Inc trades at $171.85 (market cap $420.39B). The key difference: Palantir Technologies Inc is far larger — about 17.1× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Palantir Technologies Inc nearer its low. Which is the better fit depends on your goals.
| INCY | PLTR | |
|---|---|---|
Market Cap | $24.54B | $420.39B |
Sector | Health | Technology |
52-Week High | $129.93 | $207.18 |
52-Week Low | $81.61 | $107.27 |
Enterprise Value | $20.04B | $411.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
PLTR trades at $170.50, down 2.68% today but maintains strong momentum with bullish moving averages and recent earnings beats. The company demonstrates exceptional financial performance with 84.8% gross margins and 49% net income margin, though valuation metrics remain elevated with P/E of 149.52. Recent news highlights conflicting institutional views with Cathie Wood selling while analysts maintain buy ratings.
Outlook remains positive with accelerating revenue growth and strong profitability, but high valuations and insider selling present risks. The consensus price target of $213.44 suggests 25% upside potential, though competition and market volatility could pressure the stock near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
